At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
As the uses for artificial intelligence grow within rheumatology, so do the benefits and the concerns about the technology. In a session at ACR Convergence 2025, two experts discuss the research on both sides of the debate.
In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.
Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.
The winning case study in this year’s Thieves Market highlight a case study from Malaysia with a patient who initially presented with seronegative inflammatory arthritis but experienced recurrent infections and had a porcelain aorta.
Richard F. Loeser, Jr., MD, MACR, delivering the Oscar Gluck Memorial Lecture at ACR Convergence 2025, discussed research into new treatments for osteoarthritis.
Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.
At ACR Convergence 2025, Joan T. Merrill, MD, overviewed the current research landscape of chimeric antigen receptor (CAR) T cell therapies for systemic lupus erythematosus (SLE), raising important scientific questions about these emerging treatments.